Display options
Cite
Caucanas M, Paquet P, Henry F, et al. Intense pulsed-light therapy for proliferative haemangiomas of infancy. Case Rep Dermatol Med. 2011;2011:253607doi: 10.1155/2011/253607.
Caucanas, M., Paquet, P., Henry, F., Piérard-Franchimont, C., Reginster, M. A., & Piérard, G. E. (2011). Intense pulsed-light therapy for proliferative haemangiomas of infancy. Case reports in dermatological medicine, 2011253607. https://doi.org/10.1155/2011/253607
Caucanas, Marie, et al. "Intense pulsed-light therapy for proliferative haemangiomas of infancy." Case reports in dermatological medicine vol. 2011 (2011): 253607. doi: https://doi.org/10.1155/2011/253607
Caucanas M, Paquet P, Henry F, Piérard-Franchimont C, Reginster MA, Piérard GE. Intense pulsed-light therapy for proliferative haemangiomas of infancy. Case Rep Dermatol Med. 2011;2011:253607. doi: 10.1155/2011/253607. Epub 2011 Dec 27. PMID: 23198171; PMCID: PMC3505945.
Copy Download .nbib Format: NLM
Share it on

Case Rep Dermatol Med. 2011;2011:253607. doi: 10.1155/2011/253607. Epub 2011 Dec 27.

Intense pulsed-light therapy for proliferative haemangiomas of infancy.

Case reports in dermatological medicine

Marie Caucanas, Philippe Paquet, Frédérique Henry, Claudine Piérard-Franchimont, Marie-Annick Reginster, Gérald E Piérard

Affiliations

  1. Department of Dermatopathology, University Hospital of Liège, 4000 Liège, Belgium.

PMID: 23198171 PMCID: PMC3505945 DOI: 10.1155/2011/253607

Abstract

Infantile haemangioma therapy has long been a wait-and-see policy. Since recent development of laser and light therapy, pulsed dye laser has been successfully used for treating superficial haemangiomas. Few studies have been published about treatment with intense pulsed light (IPL) to assess the risk/benefit of IPL in the treatment of infantile haemangiomas during their early proliferative phase. In the present retrospective cohort study, we retrieved data about a series of 14 Caucasian children (median age: 4.8 months) with infantile haemangiomas treated with Photoderm Vasculight flash lamp. All patients experienced a rapid regression of the haemangiomas after 3 treatments on average. Few adverse events were noted, including ulceration and crusts. No residual scarring and cosmetic damages were noticed. Fast growing haemangiomas should be treated with light therapy as soon as possible. This technology is safe, efficient, inducing regression, and preventing any further functional and aesthetic complications. The benefit-risk ratio favours the treatment of most types of haemangiomas which are out of the scope of betablocker administration.

References

  1. Am J Dermatopathol. 1985 Oct;7(5):477-88 - PubMed
  2. Lasers Surg Med. 2006 Feb;38(2):92-3 - PubMed
  3. Expert Opin Pharmacother. 2011 Mar;12(4):493-501 - PubMed
  4. J Dermatol. 2010 Nov;37(11):939-55 - PubMed
  5. Pediatr Dermatol. 2009 Jul-Aug;26(4):399-404 - PubMed
  6. Pediatrics. 1998 Mar;101(3 Pt 1):446-52 - PubMed
  7. Arch Facial Plast Surg. 2000 Apr-Jun;2(2):103-11 - PubMed
  8. J Dtsch Dermatol Ges. 2007 Nov;5(11):1036-42 - PubMed
  9. Curr Opin Pediatr. 2009 Aug;21(4):499-504 - PubMed
  10. J Eur Acad Dermatol Venereol. 2010 Jun;24(6):631-8 - PubMed
  11. An Bras Dermatol. 2010 May-Jun;85(3):307-17 - PubMed
  12. J Cosmet Laser Ther. 2010 Jun;12(3):145-50 - PubMed
  13. Lasers Surg Med. 2010 Feb;42(2):93-104 - PubMed
  14. Lasers Surg Med. 2001;28(3):273-7 - PubMed
  15. Lasers Surg Med. 2005 Oct;37(4):255-63 - PubMed
  16. J Am Acad Dermatol. 2008 Feb;58(2):261-85 - PubMed
  17. Semin Cutan Med Surg. 2010 Jun;29(2):106-14 - PubMed

Publication Types